Moderna is a biotechnology firm specializing in messenger RNA-based therapeutic medicines available in the U.S., Europe, and globally. The company develops vaccines targeting respiratory diseases including COVID-19, RSV, and influenza, as well as vaccines for latent viral infections, enteric viruses, public health threats, and bacterial conditions. Additionally, Moderna produces oncology treatments involving personalized cancer therapies and cell-based approaches, along with therapeutics for rare genetic and metabolic disorders. The company maintains partnerships with pharmaceutical firms, research institutions, government agencies, and philanthropic organizations to advance its pipeline.
1Y: 221.72 (+716.4%) · range 22.36–245.81
entry readiness 14 · NOT READY · exit proximity 35
Value area 123.92–237.63 · 6% of 120d volume overhead · clean runway
| Source | Score | Last seen |
|---|---|---|
| trend-signal | 1.000 | Oct 21, 2026 |
| trader-sentiment | 0.833 | Oct 26, 2026 |
| forum-chatter | 0.222 | Oct 30, 2026 |
none
WEAKENING · rank 5 · none
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -1.25% | -1.25% | 1/20d |
| 40d | -1.25% | -1.25% | 1/40d |